AUT 00206
Alternative Names: AUT-00206Latest Information Update: 29 Jul 2025
At a glance
- Originator Autifony Therapeutics; University of Manchester; University of Newcastle upon Tyne
- Class Antipsychotics; Benzofurans; Cyclopropanes; Ethers; Imidazolidines; Ketones; Pyrimidines; Small molecules; Spiro compounds
- Mechanism of Action Voltage-gated potassium channel modulators
-
Orphan Drug Status
Yes - Fragile X syndrome
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Fragile X syndrome
- Discontinued Schizophrenia
Most Recent Events
- 29 Jul 2025 Chemical structure information added.
- 24 Jul 2025 Phase-I development in Fragile-X-syndrome is ongoing in United Kingdom (PO, Tablet) (Autifony Therapeutics pipeline; July 2025)
- 28 Oct 2024 No recent reports of development identified for phase-I development in Fragile-X-syndrome in United Kingdom (PO, Tablet)